Literature DB >> 19146992

FTY720 and lung tumor development.

Natália Regina Antunes Salinas1, Celina Tizuko Fujiyama Oshima, Patrícia Maluf Cury, José Antonio Cordeiro, Valquiria Bueno.   

Abstract

FTY720 has been shown to prevent cancer development in experimental models but there is no report whether this beneficial effect is associated with the time point of the drug administration. Lung adenoma was induced in mice by urethane injection followed by different periods of FTY720 administration in order to evaluate lung tumor development. BALB/c mice received urethane intraperitoneally in two doses of 1.5 g/kg and were submitted to five daily doses of FTY720 (1 mg/kg/day) starting just after urethane injection (G2 n=5), 4 weeks after urethane injection (G3 n=10), 8 weeks after urethane injection (G4 n=10) and no FTY720 administration (G1 n=5). Twenty-four weeks after urethane administration mice were evaluated for the number of leukocyte in blood, lymphocytes in spleen, and lungs were evaluated for changes in histology, PCNA and VEGF expression. Lung nodules were present in higher numbers both in non treated (G1; 0.0-7.0) and FTY720 treated 8 weeks after urethane injection (G4; 0.0-6.0). G4 Group also presented the highest number of papillary nodules. G1 and G4 groups presented the lower number of splenocytes and neutrophils. In early time FTY720 treated mice (G2) we observed a slight decrease in PCNA staining and also the lower percentage of VEGF intense staining. Therefore, our data suggest that the benefits of FTY720 treatment are time-dependent and when administered in early periods after lung tumor induction this drug could impair cancer development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146992     DOI: 10.1016/j.intimp.2008.12.007

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

Review 1.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

Review 2.  S1P metabolism in cancer and other pathological conditions.

Authors:  Weng In Leong; Julie D Saba
Journal:  Biochimie       Date:  2010-02-16       Impact factor: 4.079

Review 3.  Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.

Authors:  Esther Melamed; Michael William Lee
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

4.  Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer.

Authors:  Daniela Teixeira; Joaquim Soares de Almeida; Bruna Visniauskas; Guiomar Nascimento Gomes; Aparecida Emiko Hirata; Valquiria Bueno
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

5.  FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.

Authors:  Felipe V Pereira; Denise C Arruda; Carlos R Figueiredo; Mariana H Massaoka; Alisson L Matsuo; Valquiria Bueno; Elaine G Rodrigues
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

Review 6.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.